Table 1.
Characteristics of patients by hemorrhagic transformation grade.
| No HT | HI | PH-1 | PH-2 | |
|---|---|---|---|---|
| Number | 46 | 27 | 16 | 13 |
| Female Gender, n (%) | 27 (59) | 10 (37) | 8 (50) | 8 (62) |
| Atrial Fibrillation, n (%) | 9 (20) | 11 (41) | 6 (38) | 4 (31) |
| Hypertension, n (%) | 30 (65) | 20 (74) | 10 (63) | 8 (62) |
| Diabetes, n (%) | 8 (17) | 6 (22) | 3 (19) | 2 (15) |
| Hyperlipidemia, n (%) | 16 (35) | 12 (44) | 1 (6) | 6 (46) |
| Aspirin use, n (%) | 12 (26) | 3 (11) | 4 (25) | 4 (31) |
| Age (mean ± SD), year | 71 ± 13 | 70 ± 18 | 73 ± 13 | 74 ± 16 |
| NIHSS (mean ± SD) | 13 ± 7 | 17 ± 8 | 15 ± 8 | 18 ± 4 |
| Glucose (mean ± SD), mg/dL | 133 ± 40 | 136 ± 57 | 147 ± 43 | 153 ± 61 |
| Time to treatment (mean ± SD), h | 4 ± 5 | 4 ± 4 | 12 ± 23 | 3 ± 3 |
| TREATMENT MODALITY | ||||
| IV thrombolysis, n (%) | 36 (78) | 24 (89) | 15 (94) | 10 (77) |
| IA thrombolysis, n (%) | 7 (15) | 2 (7) | 0 (0) | 2 (15) |
| Clot retrieval, n (%) | 13 (28) | 9 (33) | 5 (31) | 8 (62) |
| Post-treatment TIMI 2 or 3 | 30 (65) | 21 (78) | 14 (88) | 13 (100) |
| Visually hyperperfusion | 12 (26) | 11 (41) | 8 (50) | 7 (54) |
| VOLUME ON POST-TREATMENT MR (MEAN ± SD), ml | ||||
| ADC threshold volume | 38 ± 80 | 50 ± 98 | 37 ± 52 | 66 ± 58 |
| ASL reperfusion vol-25 | 6 ± 7 | 10 ± 13 | 21 ± 36 | 33 ± 32 |
| ASL reperfusion vol-50 | 3 ± 4 | 7 ± 9 | 15 ± 30 | 18 ± 17 |
| ASL reperfusion vol-75 | 2 ± 4 | 4 ± 7 | 11 ± 24 | 10 ± 12 |
| Relative reperfusion volume (%) | 58 ± 34 | 53 ± 34 | 63 ± 26 | 54 ± 22 |
| In hospital death, n (%) | 5 (11) | 2 (7) | 1 (6) | 5 (38) |
HT indicates hemorrhagic Transformation; IV, intravenous; IA, intra-arterial; tPA, tissue-type plasminogen activator; NIHSS, National Institutes of Health Stroke Scale; DWI, diffusion-weighted imaging; BP, blood pressure.